1
|
Abstract
The geometric structure of azido Pt(IV) compounds containing picoline was calculated by using density functional theory(DFT) at the LSDA/SDD level. The ESP distribution shows the possible reaction sites of the compounds. In addition, the frequency calculation results assigned the infrared spectra of these compounds, and specified important stretching and bending vibrations. The HOMO-LUMO energy gaps of these compounds are also calculated to explain the charge transfer of the molecules. The distribution of Mulliken charges and natural atomic charges of these atoms is also calculated. Natural bond orbital(NBO) analysis explains the intramolecular interactions and their electron density.
Collapse
Affiliation(s)
- Meilin Mu
- School of Life Science, Ludong University, Yantai, China
| | - Hongwei Gao
- School of Life Science, Ludong University, Yantai, China
| |
Collapse
|
2
|
Mu M, Zhan J, Dai X, Gao H. Research progress of azido-containing Pt(IV) antitumor compounds. Eur J Med Chem 2021; 227:113927. [PMID: 34695775 DOI: 10.1016/j.ejmech.2021.113927] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Revised: 10/10/2021] [Accepted: 10/13/2021] [Indexed: 12/11/2022]
Abstract
Cancer is a long-known incurable disease, and the medical use of cisplatin has been a significant discovery. However, the side-effects of cisplatin necessitate the development of new and improved drug. Therefore, in this study, we focused on the photoactivatable Pt(IV) compounds Pt[(X1)(X2)(Y1)(Y2)(N3)2], which have a completely novel mechanism of action. Pt(IV) can efficiently overcome the side-effects of cisplatin and other drugs. Here, we have demonstrated, summarized and discussed the effects and mechanism of these compounds. Compared to the relevant articles in the literature, we have provided a more detailed introduction and a made comprehensive classification of these compounds. We believe that our results can effectively provide a reference for the development of these drugs.
Collapse
|
3
|
Abstract
We would like to be able to design Pt(IV) prodrugs that can overcome resistance and minimize side effects. Unlike with the early exploration of Pt(II) anticancer agents where clear structure-activity relationships were defined, even after more than two decades of research on Pt(IV) prodrugs, there is no roadmap that can point us to the holy grail. Despite many excellent rational endeavors, we still have not found the "right" two axial ligands to append to the Pt(IV) derivatives of platinum(II) drugs that will "make platinum great again". So far this proved elusive, indicating that the design of Pt(IV) prodrugs is a difficult and frustrating task. Despite our better understanding of the biological processes and availability of advanced technologies, even our sophisticated rational plans often leave us disappointed and frustrated because at the end of the day, we are not able to outsmart the cancer cells or the mice, and just like Rosenberg, we might need to be rescued by serendipity.
Collapse
Affiliation(s)
- Dan Gibson
- Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, 9112102, Israel
| |
Collapse
|
4
|
Leal J, Santos L, Fernández-Aroca DM, Cuevas JV, Martínez MA, Massaguer A, Jalón FA, Ruiz-Hidalgo MJ, Sánchez-Prieto R, Rodríguez AM, Castañeda G, Durá G, Carrión MC, Barrabés S, Manzano BR. Effect of the aniline fragment in Pt(II) and Pt(IV) complexes as anti-proliferative agents. Standard reduction potential as a more reliable parameter for Pt(IV) compounds than peak reduction potential. J Inorg Biochem 2021; 218:111403. [PMID: 33730639 DOI: 10.1016/j.jinorgbio.2021.111403] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2020] [Revised: 02/13/2021] [Accepted: 02/15/2021] [Indexed: 02/07/2023]
Abstract
The problems of resistance and side effects associated with cisplatin and other chemotherapeutic drugs have boosted research aimed at finding new compounds with improved properties. The use of platinum(IV) prodrugs is one alternative, although there is some controversy regarding the predictive ability of the peak reduction potentials. In the work described here a series of fourteen chloride Pt(II) and Pt(IV) compounds was synthesised and fully characterised. The compounds contain different bidentate arylazole heterocyclic ligands. Their cytotoxic properties against human lung carcinoma (A549), human breast carcinoma (MCF7) and human colon carcinoma (HCT116 and HT29) cell lines were studied. A clear relationship between the type of ligand and the anti-proliferative properties was found, with the best results obtained for the Pt(II) compound that contains an aniline fragment, (13), thus evidencing a positive effect of the NH2 group. Stability and aquation studies in DMSO, DMF and DMSO/water mixtures were carried out on the active complexes and an in-depth analysis of the two aquation processes, including DFT analysis, of 13 was undertaken. It was verified that DNA was the target and that cell death occurred by apoptosis in the case of 13. Furthermore, the cytotoxic derivatives did not exhibit haemolytic activity. The reduction of the Pt(IV) compounds whose Pt(II) congeners were active was studied by several techniques. It was concluded that the peak reduction potential was not useful to predict the ability for reduction. However, a correlation between the cytotoxic activity and the standard reduction potential was found.
Collapse
Affiliation(s)
- Jorge Leal
- Universidad de Castilla-La Mancha, Departamento de Química Inorgánica, Orgánica y Bioquímica, Facultad de Ciencias y Tecnologías Químicas, IRICA, Avda. C. J. Cela, 10, 13071 Ciudad Real, Spain
| | - Lucia Santos
- Universidad de Castilla-La Mancha, Departamento de Química Física, Facultad de Ciencias y Tecnologías Químicas, Avda. C. J. Cela s/n, 13071 Ciudad Real, Spain
| | - Diego M Fernández-Aroca
- Universidad de Castilla-La Mancha, Laboratorio de Oncología, Unidad de Medicina Molecular, Centro Regional de Investigaciones Biomédicas, Unidad Asociada de Biomedicina UCLM, Unidad asociada al CSIC, Albacete, Spain
| | - J Vicente Cuevas
- Universidad de Burgos, Department of Chemistry, Pza. Misael Bañuelos S/N, 09001 Burgos, Spain
| | - M Angeles Martínez
- Departament de Química, Universitat de Girona, Maria Aurèlia Capmany 69, 17003 Girona, Spain
| | - Anna Massaguer
- Departamento de Biologia, Universitat de Girona, Maria Aurèlia Capmany 40, 17003 Girona, Spain
| | - Felix A Jalón
- Universidad de Castilla-La Mancha, Departamento de Química Inorgánica, Orgánica y Bioquímica, Facultad de Ciencias y Tecnologías Químicas, IRICA, Avda. C. J. Cela, 10, 13071 Ciudad Real, Spain
| | - M José Ruiz-Hidalgo
- Universidad de Castilla-La Mancha, Departamento de Química Inorgánica, Orgánica y Bioquímica, Facultad de Medicina de Albacete, Laboratorio de Oncología, Unidad de Medicina Molecular, Centro Regional de Investigaciones Biomédicas, Unidad Asociada de Biomedicina UCLM, Unidad asociada al CSIC, Albacete, Spain
| | - Ricardo Sánchez-Prieto
- Departamento de Biología del Cáncer, Instituto de Investigaciones Biomédicas De Madrid Alberto Sols (CSIC-UAM), Universidad de Castilla-La Mancha, Departamento de Ciencias Médicas, Facultad de Medicina de Albacete, Unidad Asociada de Biomedicina UCLM, Unidad asociada al CSIC, Albacete, Spain
| | - Ana M Rodríguez
- Universidad de Castilla-La Mancha, Departamento de Química Inorgánica, Orgánica y Bioquímica, Facultad de Ciencias y Tecnologías Químicas, IRICA, Avda. C. J. Cela, 10, 13071 Ciudad Real, Spain
| | - Gregorio Castañeda
- Universidad de Castilla-La Mancha, Departamento de Química Analítica y Tecnología de los Alimentos, Facultad de Ciencias y Tecnologías Químicas, Avda. C. J. Cela s/n, 13071 Ciudad Real, Spain
| | - Gema Durá
- Universidad de Castilla-La Mancha, Departamento de Química Inorgánica, Orgánica y Bioquímica, Facultad de Ciencias y Tecnologías Químicas, IRICA, Avda. C. J. Cela, 10, 13071 Ciudad Real, Spain
| | - M Carmen Carrión
- Universidad de Castilla-La Mancha, Departamento de Química Inorgánica, Orgánica y Bioquímica, Facultad de Ciencias y Tecnologías Químicas, IRICA, Avda. C. J. Cela, 10, 13071 Ciudad Real, Spain
| | - Sílvia Barrabés
- Departamento de Biologia, Universitat de Girona, Maria Aurèlia Capmany 40, 17003 Girona, Spain
| | - Blanca R Manzano
- Universidad de Castilla-La Mancha, Departamento de Química Inorgánica, Orgánica y Bioquímica, Facultad de Ciencias y Tecnologías Químicas, IRICA, Avda. C. J. Cela, 10, 13071 Ciudad Real, Spain.
| |
Collapse
|
5
|
Gibson D. Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end? J Inorg Biochem 2021; 217:111353. [PMID: 33477089 DOI: 10.1016/j.jinorgbio.2020.111353] [Citation(s) in RCA: 54] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2020] [Revised: 12/02/2020] [Accepted: 12/13/2020] [Indexed: 01/23/2023]
Abstract
Pt(IV) complexes are designed as prodrugs that are intended to overcome resistance. Pt(IV) prodrugs are activated inside cancer cells releasing cytotoxic Pt(II) drugs as well as two axial ligands that can be used to confer favorable pharmacological properties to the prodrug. The ligands can be innocent spectators, cancer targeting agents or bioactive moieties. The choice of axial ligands determines the chemical and pharmacological properties of the prodrugs. Over the years, several approaches were employed in attempts to increase the selectivity of the prodrugs to cancer cells and to utilize multi-action prodrugs to overcome resistance. In this review, we critically examine several of these approaches in order to evaluate the validity of some of the working hypotheses that are driving the current research.
Collapse
Affiliation(s)
- Dan Gibson
- Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem 9112102, Israel.
| |
Collapse
|
6
|
Qin X, Fang L, Chen F, Gou S. Conjugation of platinum(IV) complexes with chlorambucil to overcome cisplatin resistance via a "joint action" mode toward DNA. Eur J Med Chem 2017; 137:167-75. [PMID: 28586717 DOI: 10.1016/j.ejmech.2017.05.056] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2017] [Revised: 05/24/2017] [Accepted: 05/26/2017] [Indexed: 12/31/2022]
Abstract
Two platinum(IV) complexes were designed and prepared by conjugation of cisplatin and oxaliplatin units with a DNA-damaging agent, chlorambucil, respectively. By taking a joint action to enhance the damage of DNA, the conjugates displayed potent antitumor activity against all the tested cancer cell lines comparable to cisplatin and oxaliplatin, and notably could overcome cisplatin resistance at certain degree. Complex 4, a hybrid of cisplatin and chlorambucil, arrested the cell cycle at the S and G2 phases, distinctive from those of cisplatin and oxaliplatin. Apoptosis studies revealed that complex 4 could induce cell apoptosis significantly in both SGC7901 and SGC7901/CDDP cells. Moreover, further investigation indicated that complex 4 suppressed the drug resistance by the improvement of the platinum uptake and the inhibition of PRAP-1 protein. These results show that the "joint action" on DNA is an effective strategy to overcome cisplatin resistance.
Collapse
|
7
|
Hu X, Li F, Noor N, Ling D. Platinum drugs: from Pt(II) compounds, Pt(IV) prodrugs, to Pt nanocrystals/nanoclusters. Sci Bull (Beijing) 2017; 62:589-596. [PMID: 36659367 DOI: 10.1016/j.scib.2017.03.008] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2017] [Revised: 03/02/2017] [Accepted: 03/03/2017] [Indexed: 01/21/2023]
Abstract
Platinum (Pt) based drugs, such as cisplatin, are widely used as anti-cancer agents, but their severe adverse reactions and resistance of cancer patients have limited their board clinical use. For the last few decades, Pt(II) compounds, Pt(IV) prodrugs as well as smart drug delivery systems have been developed to overcome these problems. However, most conventional strategies rely on the similar anti-cancer mechanism with cisplatin and consequently only achieve limited success. Recently, Pt nanocrystals/nanoclusters (Pt NCs), with a brand new anti-cancer mechanism, have shown a promising potential in targeted cancer therapy, especially in Pt resistance circumvention. This review is helpful to understand the research strategies of Pt drugs, particularly, the recent developments and medical applications of Pt NCs.
Collapse
Affiliation(s)
- Xi Hu
- Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
| | - Fangyuan Li
- Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Key Laboratory of Biomedical Engineering of the Ministry of Education, College of Biomedical Engineering & Instrument Science, Zhejiang University, Hangzhou 310027, China
| | - Nabila Noor
- Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
| | - Daishun Ling
- Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Key Laboratory of Biomedical Engineering of the Ministry of Education, College of Biomedical Engineering & Instrument Science, Zhejiang University, Hangzhou 310027, China.
| |
Collapse
|
8
|
Yoon SI, Kim S, Cho CW, Yun YS. The Preparation of Modified Industrial Waste Polyacrylonitrile for the Adsorptive Recovery of Pt(IV) from Acidic Solutions. Materials (Basel) 2016; 9:ma9120988. [PMID: 28774109 PMCID: PMC5457015 DOI: 10.3390/ma9120988] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/04/2016] [Revised: 11/23/2016] [Accepted: 12/01/2016] [Indexed: 11/22/2022]
Abstract
Sorption technique is one of the most effective methods for recovering precious metals from wastewater solutions; however, its main drawbacks of the traditional sorbents are the slow kinetics and relatively low sorption capacities. As a solution, thin sorbent fibers have been highlighted because they can lead to fast adsorption kinetics due to their high surface areas and numerous binding sites. In this sense, the applicability of an industrial waste polyacrylonitrile (PAN) textile was examined to recover Pt(IV) from acid solutions. In order to enrich cationic functional groups on the surface of a PAN textile, the textile was chemically modified via polyethylenmine (PEI) coating. Afterwards, using PEI-coated PAN fiber, batch sorption experiments (isotherms and kinetics) and column experiments were conducted to evaluate its sorption performance toward Pt(IV). It was clearly revealed in column experiments that the PEI-coated waste PAN textile (WPAN) has fast kinetics and good performance for Pt(IV) recovery.
Collapse
Affiliation(s)
- Sung Il Yoon
- Division of Semiconductor and Chemical Engineering, Chonbuk National University, Jeonbuk 54896, Korea.
| | - Sok Kim
- Division of Semiconductor and Chemical Engineering, Chonbuk National University, Jeonbuk 54896, Korea.
- Division of Environmental Science and Ecological Engineering, College of Life Science and Biotechnology, Korea University, Seoul 02841, Korea.
| | - Chul-Woong Cho
- Division of Semiconductor and Chemical Engineering, Chonbuk National University, Jeonbuk 54896, Korea.
| | - Yeoung-Sang Yun
- Division of Semiconductor and Chemical Engineering, Chonbuk National University, Jeonbuk 54896, Korea.
| |
Collapse
|
9
|
Li J, Lyv Z, Li Y, Liu H, Wang J, Zhan W, Chen H, Chen H, Li X. A theranostic prodrug delivery system based on Pt(IV) conjugated nano-graphene oxide with synergistic effect to enhance the therapeutic efficacy of Pt drug. Biomaterials 2015; 51:12-21. [PMID: 25770993 DOI: 10.1016/j.biomaterials.2015.01.074] [Citation(s) in RCA: 83] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2014] [Revised: 01/20/2015] [Accepted: 01/25/2015] [Indexed: 01/08/2023]
Abstract
Due to their high NIR-optical absorption and high specific surface area, graphene oxide and graphene oxide-based nanocomposites have great potential in both drug delivery and photothermal therapy. In the work reported herein we successfully integrate a Pt(IV) complex (c,c,t-[Pt(NH3)2Cl2(OH)2]), PEGylated nano-graphene oxide (PEG-NGO), and a cell apoptosis sensor into a single platform to generate a multifunctional nanocomposite (PEG-NGO-Pt) which shows potential for targeted drug delivery and combined photothermal-chemotherapy under near infrared laser irradiation (NIR), and real-time monitoring of its therapeutic efficacy. Non-invasive imaging using a fluorescent probe immobilized on the GO shows an enhanced therapeutic effect of PEG-NGO-Pt in cancer treatment via apoptosis and cell death. Due to the enhanced cytotoxicity of cisplatin and the highly specific tumor targeting of PEG-NGO-Pt at elevated temperatures, this nanocomposite displays a synergistic effect in improving the therapeutic efficacy of the Pt drug with complete destruction of tumors, no tumor recurrence and minimal systemic toxicity in comparison with chemotherapy or photothermal treatment alone, highlighting the advantageous effects of integrating Pt(IV) with GO for anticancer treatment.
Collapse
Affiliation(s)
- Jingwen Li
- College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, China
| | - Zhonglin Lyv
- College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, China
| | - Yanli Li
- Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases, and College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China
| | - Huan Liu
- College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, China
| | - Jinkui Wang
- College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, China
| | - Wenjun Zhan
- College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, China
| | - Hong Chen
- College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, China.
| | - Huabing Chen
- Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases, and College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
| | - Xinming Li
- College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, China.
| |
Collapse
|